Sarilumab, a monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), has been recommended for PBS listing for patients with rheumatoid arthritis. The Pharmaceutical Benefits Advisory Committee (PBAC) has backed an application by Sanofi-Aventis for sarilumab injection 200 mg (Kevzara) to receive an Authority Required listing for the treatment of patients with severe active RA. At its ...
PBS changes for sarilumab and febuxostat
By Michael Woodhead
14 Jan 2019